Latest news with #Chardan
Yahoo
5 days ago
- Business
- Yahoo
Avidity Biosciences price target raised to $75 from $65 at Chardan
Chardan analyst Keay Nakae raised the firm's price target on Avidity Biosciences (RNA) to $75 from $65 and keeps a Buy rating on the shares after the company announced topline results from the dose escalation portion of the FORTITUDE trial and that it has received written confirmation from the FDA on an accelerated approval pathway for del-brax in Facioscapulohumeral Muscular Dystrophy using a novel circulating biomarker, cDUX. The firm's new price target reflects an increase in the estimated probability of success to 60% from 50% for del-brax targeting FSHD, the analyst tells investors. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on RNA: Disclaimer & DisclosureReport an Issue Avidity Biosciences Launches Global Phase 3 Study Avidity Biosciences announces results from Phase 1/2 FORTITUDE program Avidity announces accelerated approval regulatory pathway for Del-Brax Avidity Biosciences Reports Q1 2025 Earnings Promising Outlook for Avidity Biosciences: Buy Rating Backed by Strategic Advancements and Product Launch Preparations Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
13-05-2025
- Business
- Business Insider
Lexeo Therapeutics price target lowered to $20 from $22 at Chardan
Chardan analyst Geulah Livshits lowered the firm's price target on Lexeo Therapeutics (LXEO) to $20 from $22 and keeps a Buy rating on the shares. The firm is updating its model following the company's Q1 results, reiterated guidance on its LX2006 and LX2020 programs, as well as its update on its cash position, the analyst tells investors in a research note. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
